How to buy Intellia Therapeutics stock
Learn how to easily invest in Intellia Therapeutics stock.
Intellia Therapeutics is a biotechnology business based in the US. Intellia Therapeutics shares (NTLA) are listed on the NASDAQ and all prices are listed in US Dollars. Intellia Therapeutics employs 598 staff and has a trailing 12-month revenue of around $53 million.
How to buy Intellia Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – NTLA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Intellia Therapeutics stock price (NASDAQ: NTLA)Use our graph to track the performance of NTLA stocks over time.
Intellia Therapeutics shares at a glance
|Latest market close||$33.53|
|52-week range||$32.44 - $63.12|
|50-day moving average||$39.80|
|200-day moving average||$39.71|
|Wall St. target price||$83.71|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-5.42|
Buy Intellia Therapeutics stock from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Intellia Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Intellia Therapeutics price performance over time
|1 week (2023-09-15)||-6.39%|
|1 month (2023-08-23)||-12.57%|
|3 months (2023-06-23)||-18.18%|
|6 months (2023-03-23)||-9.82%|
|1 year (2022-09-23)||-37.82%|
|2 years (2021-09-23)||-78.40%|
|3 years (2020-09-23)||59.06%|
|5 years (2018-09-21)||25.21%|
Intellia Therapeutics financials
|Revenue TTM||$53 million|
|Gross profit TTM||$-367,858,000|
|Return on assets TTM||-23.62%|
|Return on equity TTM||-45.68%|
|Market Capitalization||$3.1 billion|
TTM: trailing 12 months
Intellia Therapeutics share dividends
We're not expecting Intellia Therapeutics to pay a dividend over the next 12 months.
Intellia Therapeutics share price volatility
Over the last 12 months, Intellia Therapeutics's shares have ranged in value from as little as $32.435 up to $63.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intellia Therapeutics's is 1.8361. This would suggest that Intellia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intellia Therapeutics overview
Intellia Therapeutics, Inc. , a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc.
Intellia Therapeutics in the news
Uranium ETF shines while ARK Genomic Revolution ETF struggles
10 Biotech Stocks with Biggest Upside
Cathie Wood Is Buying This Stock Hand Over Fist. Should You?
Frequently asked questionsWhat percentage of Intellia Therapeutics is owned by insiders or institutions?
Currently 5.343% of Intellia Therapeutics shares are held by insiders and 87.898% by institutions. How many people work for Intellia Therapeutics?
Latest data suggests 598 work at Intellia Therapeutics. When does the fiscal year end for Intellia Therapeutics?
Intellia Therapeutics's fiscal year ends in December. Where is Intellia Therapeutics based?
Intellia Therapeutics's address is: 40 Erie Street, Cambridge, MA, United States, 02139 What is Intellia Therapeutics's ISIN number?
Intellia Therapeutics's international securities identification number is: US45826J1051 What is Intellia Therapeutics's CUSIP number?
Intellia Therapeutics's Committee on Uniform Securities Identification Procedures number is: 45826J105
More guides on Finder
How to buy Discord stock when it goes public
Everything we know about the Discord IPO, plus information on how to buy in.
Today’s trending Reddit stocks
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
How to buy Tottenham Acquisition I stock
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
How to buy TotalEnergies stock
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
How to buy Thunder Bridge Acquisition stock
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
How to buy Switchback Energy Acquisition Corporation stock
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
How to buy Telefonica SA ADR stock
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
How to buy Faraday Future stock
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
How to buy Phoenix Tree stock
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
How to buy Innate Pharma stock
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.
Ask an Expert